GuruFocus DCF Analysis Reinforces Overvaluation: Intrinsic Value $111 vs Current Price $241

What happened

On October 27, 2026, GuruFocus published a DCF analysis for WM, estimating intrinsic value at $111 per share versus a market price of $241, following a recent weekly price increase. This new estimate is notably higher than the ~$73 intrinsic value from our prior FMP-based DCF, reflecting different assumptions about growth and discount rates, but it still implies the stock trades at a ~117% premium. The market price of $241 represents a significant rise from the $219.71 recorded at year-end 2025, exacerbating the valuation gap despite the higher intrinsic value figure. Our existing POTENTIAL SELL judgment was driven by rich multiples (P/E ~35x, EV/EBITDA ~17x), elevated leverage (net debt/EBITDA 3.64x), and execution risks around Stericycle and sustainability projects; the new DCF does not alter that fundamental view. Instead, it confirms that even with more optimistic DCF assumptions, WM shares remain priced well above a conservative cash-flow-based intrinsic value, leaving little margin of safety.

Implication

The new DCF from GuruFocus, while higher than our previous estimate, still suggests WM trades at more than double its intrinsic value, reinforcing the lack of a margin of safety. Given the stock's rise to $241, the risk-reward is skewed negatively: any disappointment in Stericycle integration, recycling/RNG returns, or deleveraging could trigger a significant multiple compression. Value-oriented investors should treat WM as a candidate for trimming or outright selling, as the market price already embeds optimistic growth and flawless execution. Existing holders may consider using strength to reduce exposure, while potential buyers should demand a substantial pullback—likely toward at least $150–170—before reconsidering long positions. We will continue monitoring key catalysts: healthcare segment profitability, free cash flow trajectory, and leverage reduction below 3x, which could alter our view if they improve beyond expectations.

Thesis delta

The new DCF analysis raises the intrinsic value estimate from ~$73 to $111 per share, likely due to different growth assumptions, but the stock price has also increased to $241, so the valuation gap remains wide. Our judgment remains POTENTIAL SELL; however, the overvaluation is slightly less extreme than previously calculated (117% vs 200% premium). No change in investment stance is warranted at this juncture.